PDSB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PDS Biotechnology Corp (PDSB) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows weak technical indicators, poor financial performance, and lacks significant positive catalysts or trading signals. It is better to hold off on investing in this stock at this time.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is at 22.833 (neutral zone), and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 0.659), with resistance levels at R1: 0.737 and R2: 0.761. The overall trend suggests a weak price movement with no clear upward momentum.
The analyst maintains a Buy rating, citing the stock's attractive valuation and potential impact of strategic pivots. However, no recent news or events provide additional positive catalysts.
The financial performance is poor, with a YoY drop in net income (-16.01%) and EPS (-34.48%). The stock's technical indicators are bearish, and there are no significant trading trends from hedge funds, insiders, or Congress. Additionally, the stock's trend analysis predicts a potential decline in the next week and month.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$9,009,411 (-16.01% YoY), and a significant EPS drop to -0.19 (-34.48% YoY). Gross margin remains at 0%. The financials indicate no growth and worsening profitability.
B. Riley lowered the price target from $5 to $3 but maintained a Buy rating, citing the stock's undervaluation and potential benefits from strategic pivots. However, the lowered price target reflects tempered expectations.
